Leading The Charge Against Neurological Diseases
Gladstone Institutes is an independent nonprofit research company partnered with UCSF that aspires to treat unsolved diseases through biomedical research. The company encompasses 25 research labs and 105 research operations. The launch of the startup research center aims to “provide an integrated platform for basic and clinical research, bringing together vascular biology, immunology, and neuroscience.” Institutions collaborating with the new research startup company include the University of Massachusetts, Duke University, Harvard University, and more.
The startup research company is unique in its approach to brain immunology as it factors in the role of vascular biology in the development of neurological diseases.
"We have a new appreciation of the challenges and opportunities in drug discovery for neurodegenerative diseases at the blood-brain-immune interface," said Katerina Akassoglou, founding director of the startup research center. "Innovative approaches in imaging and drug discovery platforms at our new center have the potential to transform biomedicine."
The Value of Neurological Disease Research
According to the Harvard NeuroDiscovery Center, over 6 million Americans are afflicted by some form of neurodegenerative disease. A study from the University of South Florida determined that neurological diseases cost the healthcare industry $800 billion annually.
In 2017, Microsoft co-founder Bill Gates made a personal investment of $100 million in support of companies conducting Alzheimer’s disease and dementia research. Diseases such as these are also targets of the startup research center’s scrutiny.
Market research reports that the global rare neurological disease treatment market was valued at $7.3 million in 2019 and is expected to reach a value of $13.8 billion by 2027. Novartis, a pharmaceutical manufacturer and neurological research company, boasts a market cap of just over $229 billion.
The Gladstone-UCSF Center for Neurovascular Brain Immunology, a new research startup company targeting neurological diseases and novel treatments, was launched with backing from a $2.5 million donation from the Simon Family Trust. The research center hopes to employ a unique understanding of vascular biology to better understand and potentially cure neurodegenerative diseases.
About the Author
James White is a Michigan State University graduate with a B.S. in Environmental Biology. He is interested in reporting emerging trends in technology, especially with regard to alternative energy and environmental conservation.